Gerot-Lannacher

What Gerot-Lannacher does

Gerot-Lannacher, operating commercially as GL Pharma, is an Austrian pharmaceutical company headquartered in Lannach, Austria, that develops, manufactures, and commercializes both branded pharmaceuticals and generic drugs. The company focuses on innovative and generic proprietary developments in specialized indication areas, with particular expertise in substitution therapy medications for drug addiction treatment. Its portfolio addresses severe and chronic conditions and is distributed through Austria's healthcare supply chain via general practitioners, pharmacists, and pharmaceutical wholesalers, with international reach pursued through licensing partnerships.

The company's go-to-market is B2B sales-led, targeting vertical healthcare segments rather than end consumers. Revenue is generated through the development, production, and commercialization of pharmaceutical products, supplemented by out-licensing of proprietary products to international partners. Pricing is not publicly disclosed. The company maintains a web-based resource center distributing product catalogues and reports, and engages in top-of-funnel brand presence through LinkedIn, Instagram, and Facebook.

Operationally, the company functions as a privately held specialty pharmaceutical manufacturer with no disclosed parent company, subsidiaries, or funding rounds. Corporate social media and website activity (© 2026) confirm active operations. No information on headcount, financial performance, leadership, or M&A activity is available in the source data, representing a material information gap for investors.

Name

Gerot-Lannacher

Legal name

Gerot-Lannacher

Website

https://gl-pharma.at

Company type

Private

Operating status

Operating

Short description

Gerot-Lannacher (GL Pharma) is an Austrian specialty pharmaceutical company that develops, manufactures, and commercializes branded and generic drugs for severe and chronic conditions, including substitution therapy for drug addiction, selling through Austrian healthcare channels and international licensing partners.

Ownership category

akta.pro rank

Product category

Pharmaceuticals

NAICS

Pharmaceutical and Medicine Manufacturing (32541)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Small-Molecule Generics (Branded/Unbranded) (HLAIABAA)

akta.pro secondary industry

Primary Care & General Medicine Pharmaceuticals (HLAIAAAA)

Keywords

• Pharmaceutical manufacturing
• Generic pharmaceuticals
• Branded pharmaceuticals
• Substitution therapy
• Drug addiction treatment

Headquarters

HQ city

Lannach

HQ country

Austria

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Technology or R&D, Personnel, Marketing or Sales

Revenue model

1. Pharmaceutical Products: Revenue generated from development, production, and commercialization of brand name pharmaceuticals and generic drugs for treatment of severe and chronic conditions. Products are distributed through healthcare sector partners including general practitioners, pharmacists, and pharmaceutical wholesalers.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Gerot-Lannacher (GL Pharma) develops, produces, and commercializes branded pharmaceuticals and generic medicines focused on treating severe and chronic disease states. The portfolio includes medication-assisted substitution therapy products used in the treatment of drug addiction. Distribution is conducted through general practitioners, pharmacists, and pharmaceutical wholesalers, with additional licensing arrangements for international partners.

Product overview

GL Pharma operates as a pharmaceutical company developing, producing, and commercializing both unique brand name products and generic pharmaceuticals. The company focuses on innovative and generic proprietary developments in specialized indication areas for the treatment of severe and chronic conditions. Their portfolio includes brand name pharmaceuticals and generics distributed in Austria and internationally, with specific expertise in substitution therapy for drug addiction treatment. They partner with general practitioners, pharmacists, and pharmaceutical wholesalers as suppliers to Austria's healthcare sector.

Differentiator

Problem solved

Functional benefit

Products and services

• Branded Pharmaceuticals

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Two partnerships are on record, tiered core.

• Licensing PartnerscoreOEM/ Whitelabel/ Licensing PartnerGL Pharma offers licensing opportunities for their pharmaceutical products, allowing international partners to commercialize their innovative medicines in different markets.
• Research & Development PartnerscoreStrategic or Co-development PartnerCollaborative partnerships focused on innovative and generic proprietary developments in specialized indication areas. The company is committed to continuous investment in pharmaceutical research and development.

Scale indicators1 record

Recent moves4 records

Expansion highlights5 records

Direct peers

• Polpharma: Polish generics and branded-generics manufacturer with European distribution and growing specialty portfolio. Comparable hybrid model targeting CEE and broader EU markets with manufacturing-led economics.
• KRKA: Slovenian manufacturer of generic and specialty branded pharmaceuticals sold primarily across CEE and Western Europe. Comparable portfolio mix, manufacturing-led model, and growing focus on higher-value specialty indications.
• Gedeon Richter: Hungarian pharma group combining branded generics with proprietary innovation, including specialty CNS and women's health franchises. Comparable hybrid model, EU manufacturing base, and international licensing strategy.
• STADA Arzneimittel: German-headquartered private-equity-owned pharma combining generics and specialty branded products across Europe. Highly comparable dual branded-generics model, similar mid-cap European footprint, and overlapping distribution through wholesalers and pharmacies.
• Camurus: Swedish specialty pharma with a leading franchise in opioid dependence and substitution therapy. Overlaps directly with GL Pharma's substitution-therapy specialty and EU focus on addiction medicine.
• Indivior: UK/US specialty pharma focused on opioid dependence and addiction treatment. Direct overlap with GL Pharma's substitution-therapy franchise and chronic-condition specialty positioning.

Broad incumbents

• Sandoz (Novartis): Global generics and biosimilars leader spun out of Novartis. Overlaps with GL Pharma's generics and selective specialty lines, but operates at vastly greater scale and geographic breadth.
• Teva Pharmaceutical Industries: World's largest generics manufacturer with branded specialty franchises including CNS and pain. Broad overlap with GL Pharma's dual branded-generics strategy, but at global incumbent scale.
• Viatris: Global pharma formed from Mylan-Upjohn combining established branded specialty with broad generic portfolio. Competes across many of the same therapeutic areas and distribution channels as GL Pharma, particularly in Europe.

Emerging players

• Zambon: Italian privately held pharma with branded specialty in CNS, pain, and rare diseases alongside generics. Comparable European mid-cap footprint and growing focus on specialty therapeutics adjacent to GL Pharma's portfolio.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

• Facebookfacebook.com/gl.pharma
• LinkedInlinkedin.com/company/g-l-pharma
• Instagraminstagram.com/gl.pharma

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Gerot-Lannacher